Developing a new treatment for tuberculosis called Telacebec.
Official title: PROCESS DEVELOPMENT OF TELACEBEC FOR TUBERCULOSIS
Funded at Midwest Research Institute · NIH-11219854 · Data updated 2026-11-12
This study is testing a new medication called Telacebec (Q203) to see if it can help people with tuberculosis by making treatment safer and more effective, which could lead to shorter recovery times and better health outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Midwest Research Institute NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2026 |
| Funding year | 2024 |
| Award (this year) | $605,287 |
| NIH project number | 75N95024D00012-0-759502400002-1 |
| Project ID | NIH-11219854 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those who may not respond well to existing treatments.
✕Less likely to help
Patients with non-tuberculosis infections or those who do not have a confirmed diagnosis of tuberculosis may not receive any benefit from this research.
What this research studies
This research focuses on the development of Telacebec (Q203), a new medication aimed at treating tuberculosis. The project involves supporting the chemistry, manufacturing, and controls necessary to ensure the drug is safe and effective for patients. By refining the processes involved in creating this treatment, the research aims to improve the overall management of tuberculosis infections. Patients may benefit from a more effective therapy that could potentially shorten treatment duration and improve outcomes.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective treatment option for tuberculosis.
How similar studies have gone: Other research has shown promise in developing new tuberculosis treatments, but the specific approach of Telacebec is relatively novel.
Where this research is happening
-
Midwest Research Institute
Kansas City, United States Active
Researchers
- Principal investigator: Slade, Desmond — Midwest Research Institute
- Study coordinator: Slade, Desmond
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.